Pharmsynthez is a rapidly growing innovative pharmaceutical company founded in 1996. It is the first Russian biopharmaceutical company to go public in 2010 and has a portfolio of innovative drugs with high commercial potential in the US and EU pharmaceutical markets. What sets Pharmsynthez apart from other Russian biopharmaceutical manufacturers is its unique specialization in the production and promotion of innovative drugs, as well as its ability to conduct contract R&D.

The company operates a modern, high-tech complex for the production of pharmaceutical substances, ensuring strict adherence to GMP standards. Pharmsynthez is involved in the entire process, from laboratory development of molecules and active chemical compounds to the industrial-scale production of finished pharmaceutical products. Its portfolio includes Vazostenon, GlauMax, Neovir, Neostim, Segidrin, Fenazid, and Fludarabel.

With a commitment to quality and innovation, Pharmsynthez is revolutionizing the pharmaceutical industry in Russia